Bridging bench to body : ex vivo models to understand articular cartilage repair
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
With little to no ability to self-regenerate, human cartilage defects of the knee remain a major clinical challenge. Tissue engineering strategies include delivering specific types of cells and biomaterials to the injured cartilage for restoration of architecture and function. Pre-clinical models to test the efficacy of the therapies come with high costs and ethical issues, and imperfect prediction of performance in humans. Ex vivo models represent an alternative avenue to trial cartilage tissue engineering. Defined as viable explanted cartilage samples, ex vivo models can be cultured with a cell-laden biomaterial or tissue-engineered construct to evaluate cartilage repair. Though human and animal ex vivo models are currently used in the field, there is a need for alternative methods to assess the strength of integration, to increase throughput and manage variability and to optimise and standardise culture conditions, enhancing the utility of these models overall.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
Current opinion in biotechnology - 86(2024) vom: 01. März, Seite 103065 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trengove, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.copbio.2024.103065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36790957X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36790957X | ||
| 003 | DE-627 | ||
| 005 | 20240318234158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.copbio.2024.103065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM36790957X | ||
| 035 | |a (NLM)38301593 | ||
| 035 | |a (PII)S0958-1669(24)00001-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trengove, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bridging bench to body |b ex vivo models to understand articular cartilage repair |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a With little to no ability to self-regenerate, human cartilage defects of the knee remain a major clinical challenge. Tissue engineering strategies include delivering specific types of cells and biomaterials to the injured cartilage for restoration of architecture and function. Pre-clinical models to test the efficacy of the therapies come with high costs and ethical issues, and imperfect prediction of performance in humans. Ex vivo models represent an alternative avenue to trial cartilage tissue engineering. Defined as viable explanted cartilage samples, ex vivo models can be cultured with a cell-laden biomaterial or tissue-engineered construct to evaluate cartilage repair. Though human and animal ex vivo models are currently used in the field, there is a need for alternative methods to assess the strength of integration, to increase throughput and manage variability and to optimise and standardise culture conditions, enhancing the utility of these models overall | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Biocompatible Materials |2 NLM | |
| 700 | 1 | |a Duchi, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Onofrillo, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Sooriyaaratchi, Dulani |e verfasserin |4 aut | |
| 700 | 1 | |a Di Bella, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connor, Andrea J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in biotechnology |d 1990 |g 86(2024) vom: 01. März, Seite 103065 |w (DE-627)NLM012635251 |x 1879-0429 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2024 |g day:01 |g month:03 |g pages:103065 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.copbio.2024.103065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2024 |b 01 |c 03 |h 103065 | ||